RxDoctor Payments Data

Linda Garrett

Family · Hamilton, MSNPI 1679021588

Payments from drug & device makers

$437in general payments, 2019–2025

Across 17 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$145
  • Amgen$75
  • Jazz Pharmaceuticals Inc.$43
  • Harmony Biosciences LLC$38
  • Lilly USA, LLC$33
  • Amneal Pharmaceuticals LLC$25
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$437100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$437 in reported general payments places this provider in the 50th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$101,330
Medicare patients
195
Services billed
4,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$53,171
MounjaroTirzepatide23$40,506
JardianceEmpagliflozin22$19,167
FarxigaDapagliflozin Propanediol22$16,326
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,884
LinzessLinaclotide22$11,929
EliquisApixaban11$7,610
Repatha SureclickEvolocumab11$6,937
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,653
Novolog FlexpenInsulin Aspart11$2,166
Gabapentin116$1,635
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen90$1,541
Albuterol Sulfate HfaAlbuterol Sulfate43$1,466
Duloxetine Hcl69$1,435
Omeprazole95$1,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$33$40,50623 claims
AstraZenecaFarxiga, Breztri Aerosphere$145$29,21040 claims
AbbVieLinzess, Synthroid$18$12,69935 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$65394 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,007 family providers in Mississippi.

Other family in Hamilton

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →